The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

被引：79

作者：

Jit, Mark ^{[1
]}

Bilcke, Joke ^{[2
]}

Mangen, Marie-Josee J. ^{[3
]}

Salo, Heini

Melliez, Hugues ^{[4
]}

Edmunds, W. John ^{[5
]}

Yazdan, Yazdanpanah ^{[4
]}

Beutels, Philippe ^{[2
]}

机构：

[1] Univ Birmingham, Hlth Econ Unit, Birmingham B15 2TT, W Midlands, England

[2] Univ Antwerp, CHERMID, Vaccine & Infect Dis Inst VAXINFECTIO, Antwerp, Belgium

[3] Univ Med Ctr Utrecht, Jujius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands

[4] Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, Tourcoing, France

[5] London Sch Hyg & Trop Med, London, England

来源：

VACCINE | 2009年 / 27卷 / 44期

关键词：

Rotavirus; Vaccination; Cost-effectiveness; EFFICACY; DISEASE; SAFETY; GASTROENTERITIS; AUSTRALIA; VACCINES; INFANTS; BURDEN; CHOICE;

D O I：

10.1016/j.vaccine.2009.08.030

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix (R), 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of (sic)30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix (R) (excluding administration costs) to be cost effective was (sic)41 in Belgium, (sic)28 in England and Wales, 4651 in Finland, (sic)36 in France and (sic)46 in the Netherlands. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：6121 / 6128

页数：8

共 41 条

[21] Cost and cost-effectiveness of childhood vaccination against rotavirus in France [J].

Melliez, H. ;

Levybruhl, D. ;

Boelle, P. Y. ;

Dervaux, B. ;

Baron, S. ;

Yazdanpanah, Y. .

VACCINE, 2008, 26 (05) :706-715

[22]

*NAT PUBL HLTH I F, 2009, VACC COV CHILDR BORN

[23]

National Institute for Health Clinical Excellence, 2008, UPD GUID METH TECHN

[24] The cost-effectiveness of rotavirus vaccination in Australia [J].

Newall, Anthony T. ;

Beutels, Philippe ;

Macartney, Kristine ;

Wood, James ;

MacIntyre, C. Raina .

VACCINE, 2007, 25 (52) :8851-8860

[25] Cost-effectiveness analyses of human papillomavirus vaccination [J].

Newall, Anthony T. ;

Beutels, Philippe ;

Wood, James G. ;

Edmunds, W. John ;

MacIntyre, C. Raina .

LANCET INFECTIOUS DISEASES, 2007, 7 (04) :289-296

[26] Burden of severe rotavirus disease in Australia [J].

Newall, Anthony T. ;

MacIntyre, Raina ;

Wang, Han ;

Hull, Brynley ;

Macartney, Kristine .

JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (09) :521-527

[27] Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands - The Dutch results from the EUROMET project [J].

Rijkom, JEFZ ;

Leufkens, HGM ;

Busschbach, JJV ;

Broekmans, AW ;

Rutten, FFH .

PHARMACOECONOMICS, 2000, 18 (02) :149-160

[28]

Salo H, 2007, EUR J PUBLIC HEALTH, V17, P210

[29] Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations [J].

Santosham, M ;

Moulton, LH ;

Reid, R ;

Croll, J ;

Weatherbolt, R ;

Ward, R ;

Forro, J ;

Zito, E ;

Mack, M ;

Brenneman, G ;

Davidson, BL .

JOURNAL OF PEDIATRICS, 1997, 131 (04) :632-638

[30]

SENECAL M, 2006, 7 CAN IMM C OTT CAN

← 1 2 3 4 5 →